Video: Every Case Tells a Story| Webinar: ACR/CHEST ILD Guidelines in Practice

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

  • Conditions
    • Axial Spondyloarthritis
    • Gout and Crystalline Arthritis
    • Myositis
    • Osteoarthritis and Bone Disorders
    • Pain Syndromes
    • Pediatric Conditions
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
    • Systemic Sclerosis
    • Vasculitis
    • Other Rheumatic Conditions
  • FocusRheum
    • ANCA-Associated Vasculitis
    • Axial Spondyloarthritis
    • Gout
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Systemic Lupus Erythematosus
  • Guidance
    • Clinical Criteria/Guidelines
    • Ethics
    • Legal Updates
    • Legislation & Advocacy
    • Meeting Reports
      • ACR Convergence
      • Other ACR meetings
      • EULAR/Other
    • Research Rheum
  • Drug Updates
    • Analgesics
    • Biologics/DMARDs
  • Practice Support
    • Billing/Coding
    • EMRs
    • Facility
    • Insurance
    • QA/QI
    • Technology
    • Workforce
  • Opinion
    • Patient Perspective
    • Profiles
    • Rheuminations
      • Video
    • Speak Out Rheum
  • Career
    • ACR ExamRheum
    • Awards
    • Career Development
  • ACR
    • ACR Home
    • ACR Convergence
    • ACR Guidelines
    • Journals
      • ACR Open Rheumatology
      • Arthritis & Rheumatology
      • Arthritis Care & Research
    • From the College
    • Events/CME
    • President’s Perspective
  • Search

Novel Bone Drug Promising in Postmenopausal Osteoporosis

Reuters Staff  |  August 7, 2017

NEW YORK (Reuters Health)—The investigational drug romosozumab led to gains in hip bone mineral density (BMD) that were not seen with teriparatide in older women with osteoporosis transitioning from bisphosphonate therapy in the STRUCTURE study.

Amgen’s romosozumab is a monoclonal antibody that inhibits sclerosin, a negative regulator of bone formation. In addition to stimulating bone formation, it also inhibits bone resorption.

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

Results of the Phase 3 STRUCTURE study suggest that romosozumab “[may] be an effective treatment option for patients at increased risk for fracture who are transitioning from oral bisphosphonate therapy,” write Dr. Bente Langdahl, from Aarhus University Hospital in Denmark, and colleagues in The Lancet, online July 26.1

The study was funded by Amgen, Astellas and UCB Pharma.

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

The study enrolled 436 women with postmenopausal osteoporosis who had taken an oral bisphosphonate for at least three years prior to screening and alendronate in the year before screening. The women had areal BMD T-scores of -2.5 or lower at the total hip, lumbar spine, or femoral neck and a history of vertebral or nonvertebral fracture. They received daily calcium and vitamin D and were randomly assigned to subcutaneous romosozumab (210 mg monthly) or subcutaneous teriparatide (20 mcg daily).

Through 12 months, the mean percent change from baseline in total hip areal BMD was +2.6% in the romosozumab arm vs. -0.6% in the teriparatide arm, a significant difference (P<0.0001).

At six and 12 months, the mean percent changes from baseline in areal BMD at the femoral neck and lumbar spine were also significantly greater with romosozumab than with teriparatide.

Significant gains in integral and cortical volumetric BMD and estimated hip strength were seen with romosozumab at 12 months, whereas integral BMD at the hip and estimated hip strength declined with teriparatide. “These results suggest that romosozumab might offer a unique benefit to patients with postmenopausal osteoporosis who are transitioning from bisphosphonate therapy,” write Dr. Langdahl and colleagues.

Overall, romosozumab was well tolerated with no new safety concerns, they say. The most frequently reported adverse events were nasopharyngitis (13% of patients in the romosozumab arm and 10% of patients in the teriparatide group), hypercalcemia (<1% vs. 10%), and arthralgia (10% vs. 6%). Three patients on romosozumab developed hypocalcemia, compared with none on teriparatide.

Serious adverse events were reported in 8% patients on romosozumab and in 11% on teriparatide; none were judged to be treatment-related.

In an invited comment in The Lancet, Dr. Juliet Compston of the Cambridge Biomedical Campus, in Cambridge, U.K., notes that in clinical practice, “it is not uncommon to encounter patients who despite adequate adherence to medication apparently do not respond to oral bisphosphonates, with persistently low BMD or incident fracture during treatment. Some of these patients might respond to intravenous bisphosphonate therapy, but in others switching to a drug that stimulates bone formation is a reasonable approach.”2

She adds, “Although the effects on fracture risk have not been established, the results of the study by Langdahl and colleagues suggest that the greatest benefits for hip BMD and estimated strength are obtained with a drug such as romosozumab that stimulates bone formation and inhibits bone resorption.”

“Use of sequential therapy in osteoporosis is the focus of much attention, and this study shows the potential for the use of drugs with different mechanisms of action as a strategy to improve outcomes in the management of osteoporosis. Since the duration of therapy with bone-forming agents is limited and bone loss follows treatment withdrawal, the subsequent use of interventions to maintain treatment benefits is an important area for future research,” Dr. Compston concludes.

Dr. Langdahl and several coauthors have disclosed financial relationships with Amgen, UCB Pharma, and other pharmaceutical companies. Dr. Compston has received speaking fees from Amgen for a talk on the treatment gap in osteoporosis.


References

  1. Langdahl BL, Libanati C, Crittenden DB, et al. Romosozumab (sclerostin monoclonal antibody) versus teriparatide in postmenopausal women with osteoporosis transitioning from oral bisphosphonate therapy: A randomised, open-label, phase 3 trial. Lancet. 2017 Jul 26. pii: S0140-6736(17)31613-6. doi: 10.1016/S0140-6736(17)31613-6. [Epub ahead of print]
  2. Compston J. Bone-forming agents in non-responders to bisphosphonates. Lancet. 2017 Jul 26. pii: S0140-6736(17)31824-X. doi: 10.1016/S0140-6736(17)31824-X. [Epub ahead of print]

Page: 1 2 | Multi-Page
Share: 

Filed under:Biologics/DMARDsConditionsDrug UpdatesOsteoarthritis and Bone Disorders Tagged with:bone mineral density (BMD)Osteoporosisosteoporosis treatmentspostmenopauseromosozumab

Related Articles

    Unexpected Benefits of Bisphosphonates after Hip Fracture

    February 3, 2012

    Recent trials show this bisphosphonates can reduce subsequent hip fractures and mortality, while remaining cost effective.

    Diagnosis, Management of Medication-Induced Osteonecrosis of the Bone

    October 13, 2015

    Prior to the widespread use of bisphosphonates for the manage­ment of osteoporosis, multiple myeloma and metastatic cancer to the skeletal system, osteonecrosis of the jawbones was an infrequent condition seen after radiation for oral cancers (osteoradionecrosis) and in chronic odontogenic infections.1 Since the mid-2000s, osteonecrosis of the jawbones has been noted to occur as a…

    Build Up Bone

    June 1, 2007

    Current management of osteoporosis

    Romosozumab Promising for Osteoporosis Treatment; Setbacks for Fulranumab Clinical Trials

    April 27, 2016

    Two studies have shown that romosozumab is effective for increasing bone mineral density in both men and women with osteoporosis. And due to safety concerns, Janssen has dropped out of clinical trials for fulranumab, which is being studied to treat OA pain…

  • About Us
  • Meet the Editors
  • Issue Archives
  • Contribute
  • Advertise
  • Contact Us
  • Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies. ISSN 1931-3268 (print). ISSN 1931-3209 (online).
  • DEI Statement
  • Privacy Policy
  • Terms of Use
  • Cookie Preferences